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Abstract
Introduction: Interleukin-10 (IL-10) producing B cells, also known as regulatory B (Breg) cells, play a key role in
controlling autoimmunity. Our laboratory and others have demonstrated a pivotal role for Bregs in rheumatological
disorders, including experimental models of arthritis and lupus. The aim of this study was to identify the role of
endogenous IL-10 secreting B cells in vivo in controlling the induction and disease progression of collagen-induced
arthritis (CIA).
Methods: We generated chimeric mice that had IL-10 knocked-out specifically in the B cell population. These mice
were compared with wild-type (WT) B cell chimeric mice for their susceptibility to CIA.
Results: Here we report that chimeric mice specifically lacking IL-10 producing B cells (IL-10-/- B cell) developed an
exacerbated CIA compared to chimeric wild type B cell (WT B cell) mice. A marked increase in inflammatory Th1
and Th17 cells were detected in IL-10-/-B cell mice compared to WT B cell mice. Furthermore, there was a
reduction in IL-10 secreting CD4+ Tr1 cells in these animals.
Conclusions: IL-10 producing B cells restrain inflammation by promoting differentiation of immuno-regulatory over
pro-inflammatory T cells and, hence, act to maintain tolerance.
Introduction
CIA-induced joint destruction is widely accepted to
develop as a result of the secretion of pro-inflammatory
Th1 cytokines, such as IFNg and IL-12 [1-3]. These Th1
cytokines facilitate the infiltration of neutrophils and
macrophages into the joint, which stimulates the pro-
duction of both TNFa and IL-1 that ultimately results
in joint destruction and pannus formation [4,5]. In addi-
tion to this, CIA is mediated by pathogenic B cells,
which produce anti-collagen antibodies that are indica-
tive of disease development [5] and can induce arthritis
upon transfer [6,7]. This taken together with the fact
that B cell deficient mice (μMT) are resistant to CIA [8]
shows that CIA is both a T and B cell-mediated disease.
The role of IL-10 has been well documented in
experimental arthritis [9-13] and other autoimmune dis-
orders [14-18]. It has been shown that CIA is exacer-
bated in IL-10 deficient DBA mice [12], although the
relevant contributions of IL-10 secreted by T cells and B
cells cannot be revealed using IL-10-/- animals. The
importance of B cell derived IL-10 in CIA has been con-
firmed by previous work in this laboratory [9,10]. Sev-
eral regulatory B cell subsets have now been identified
and most share the release of IL-10 as a common
mechanism of action. In experimental arthritis, we have
shown that the transfer of the main producers of IL-10,
namely CD19+CD21hiCD23hiCD1dhi transitional 2 mar-
ginal zone precursor B cells (T2-MZP), prevents or
ameliorates established disease [9,19]. Similarly, transfer
of CD5+CD1dhi B cells (B10) controls the development
of the contact hypersensitivity response (CHS) [20]. In
each instance, Bregs isolated from IL-10 deficient mice
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(IL-10-/-) mice failed to suppress the development of
autoimmune diseases [21-25]. In order to assess the
importance of all subsets of IL-10 secreting regulatory B
cells, we generated chimeric mice that lack IL-10 specifi-
cally on all B cells. Thus, providing us with a unique
environment to assess the role of B cell derived IL-10 in
joint inflammation.
Previous work in this laboratory has shown a pivotal
role for endogenous B cell-derived IL-10 in the context
of antigen induced arthritis (AIA) [19]. AIA is induced
by immunization with mBSA emulsified in Complete
Freunds Adjuvant (CFA), followed a week later by intra-
articular injection with mBSA [26]. The incidence of
disease (that is, antigen-mediated joint swelling) is 100%
and the disease is characterized by acute inflammation
which is resolved within one month [27]. In the latter
stages of disease, anti-mBSA antibodies are also pro-
duced [28], hence, this model incorporates both the
DTH response and the development of an autoimmune-
like disease. IL-10-/- B cell mice have an exacerbated
AIA arthritis phenotype, including increased clinical
scores and knee swelling, enhanced Th17 and Th1
development and a reduction in regulatory T cells [19].
Next we wanted to elucidate and validate the role of IL-
10 secreting Bregs in CIA, a polyarthritis model involving
both severe inflammation and cartilage and bone erosion.
CIA differs from AIA in several key areas. CIA cannot be
induced in B cell deficient mice, whereas AIA is a predo-
minantly T- cell mediated disease that can be induced in
B cell deficient mice that develop an exacerbated AIA
[8,19]. Additionally, different genetic backgrounds and
modes of immunizations are commonly used. The
courses of these diseases are also significantly different.
AIA is a monoarthritis, which can be resolved in under
one month, whereas CIA can take several months to
develop and can go into remission in one or more paws.
In this paper, we have shown that in animals lacking
IL-10 specifically on their B cells, T cell differentiation
is skewed to pro-inflammatory Th1 and Th17 subtypes,
at the expense of the differentiation and maintenance of
immune-regulatory Tr1 cells. These conditions result in
exacerbated experimental arthritis in IL-10-/- B cell mice
as compared to WT B cell mice.
Materials and methods
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Animals and antibodies
IL-10-/- and μMT animals on the H2q background were
generated by backcrossing the original IL-10/H2b and
μMT/H2b with DBA/1 H2q mice. The mice were typed
by PCR, and IL-10 KO-/-H2q were further backcrossed
into DBA/1. Mice from the 15th generation (DBA/1IL-
10 KO-/-) were used for experiments. All animals were
bred and maintained under specific pathogen-free con-
ditions at the animal facility at University College Lon-
don, UK. All antibodies were purchased from BD
Biosciences, Oxford, UK.
Generation of chimeric mice
Chimeric mice were generated as previously published
[17]. Briefly, recipient μMt mice received 800 cGy of g-
irradiation via a caesium source. Five hours following
irradiation recipients received 2 × 106 donor bone mar-
row cells. Bone marrow preparations were depleted of T
cells by negative selection with a MACS magnetic col-
umn (Miltenyi Biotech, Bergisch Gladbach, Germany).
To generate mice where the absence of IL-10 was exclu-
sively restricted to B cells, μMT mice were reconstituted
with a mixture of bone marrow consisting of 80% from
μMT (no B cell differentiation) with 20% from IL-10-/-
mice. Control mice received 80% from μMT and 20%
bone marrow from WT mice (to give a normal B cell
compartment). Two additional control groups were
included: 100% of bone marrow from μMT into WT
recipients (control for the absence of B cells) or 80%
WT and 20% IL-10-/- bone marrow into μMT recipients
(this will assess the effect of 20% reduction in IL-10 pro-
duction by non-B cell lymphocytes in the response
observed). Chimeras were left to fully reconstitute their
peripheral lymphoid system over at least eight weeks
before use in CIA experiments. The absence of B cells
(CD19-expressing splenocytes) in the group that
received 100% μMT bone marrow confirmed the total
ablation of the host bone marrow by irradiation. In con-
trast, the three other groups showed numbers of CD19+
B cells and CD4+T cells equivalent to numbers found in
non chimeric WT B6 mice.
Induction and assessment of collagen-induced arthritis
and histology of joints
Male DBA/1 mice were immunized with 100 μg of type II
bovine collagen (CII) emulsified in CFA (Diffco Labora-
tories, Oxford, UK) as previously described [9]. The devel-
opment of arthritis was assessed daily for the duration of
the experiment. The clinical severity of arthritis was
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graded as follows: 0, normal; 1, slight swelling and/or
erythema; 2, pronounced edematous swelling; 3, pro-
nounced edematous swelling plus joint rigidity; and 4, lax-
ity. Each limb was graded, allowing a maximal clinical
score of 16 for each animal. All clinical evaluations were
performed in a blinded manner. All the mice are kept in
accordance with the local guidelines.
Hind paws were removed post-mortem and fixed in
10% (w/v) buffered formalin and decalcified in 5% EDTA.
After decalcification, the paraffin sections were stained
with hematoxylin-eosin. Two independent observers
evaluated the slides histologically. The slides were graded
as: 0, normal, no damage; 1, minimal synovitis, cartilage
loss, and bone erosion limited to discrete foci; 2, synovitis
and erosion present, but normal joint architecture intact;
and 3, extensive erosion and joint architecture disrupted.
Serum anti-collagen antibody levels
Anti-CII Abs were determined as previously described
[29]. Briefly, microplates (Nunc) were coated with (2 μg/
ml) bovine CII overnight, blocked with 2% BSA and then
incubated with serial dilutions of the testing sera. Bound
IgG1 and IgG2a were detected by incubation with alka-
line phosphatase-conjugated sheep anti-mouse IgG1 and
IgG2a respectively (The Binding Site, Schwetzingen, Ger-
many) followed by TMB (Sigma, St Louis, MO, USA).
Flow cytometric analysis of intracellular cytokine
synthesis
Intracellular cytokine analysis was performed as pre-
viously described [10]. Briefly, inguinal lymph node cul-
tures were suspended at 5 × 105 cells/ml in complete
medium with PMA (50 ng/ml Sigma-Aldrich, St Louis,
MO, USA), ionomycin (500 ng/ml Sigma-Aldrich, St
Louis, MO, USA) and GolgiPlug (BD Biosciences,
Oxford, UK) for five hours. Cells were then stained with
extracellular markers, followed by permeabilization and
incubation with anti-mouse IL-10 APC, IFNg APC or
IL-17 PE mAbs. The cells were acquired with a BD LSR
flow cytometer (BD Biosciences, Oxford, UK) and ana-
lysed using FlowJo software.
In vivo cytokine capture assay
This was carried out using BD in vivo IFNg and IL-2
capture assay kits. Briefly, mice were injected intraperi-
toneally with 10 μg of NA/LE biotin-conjugated anti-
mouse IFNg antibody in 200 μL in sterile PBS. Blood
samples were collected from injected mice after 12
hours, and serum was isolated. Serum cytokine levels
were then analyzed using an ELISA based method.
Cytokine secretion assay
Lymph node cultures were suspended at 5 × 105 cells/
ml in complete medium with anti-CD3 (1 μg/ml). After
incubation at 37°C for 48 hours, the plates were centri-
fuged; the supernatants were collected and stored at -
80°C until further analysis. Cytokine concentration in
the supernatants was determined using mouse Th1/Th2
cytokine FlowCytomix kit (Bender Medsystems, Aachen-
Germany), following the manufacturer’s instructions.
Regulatory T cell suppression assay/proliferation assay
Spleens were removed post-mortem and CD4+T cells,
Treg and Teff cells were negatively isolated. Cells were
cultured for 60 hours with either complete medium or
with anti-CD3 (1 μg/ml). Cultures were then pulsed
overnight with 1 μCi of (H3) thymidine, harvested and
counted in a scintillation counter (LKB Instruments, Mt
Waverley, Victoria, Australia).
Statistical analysis
For the statistical analysis of the data, the Mann-Whit-
ney U test and the Fisher exact test were applied to ana-
lyze clinical results. Unpaired t tests were applied in all
other experiments. P < 0.05 was considered significantly
different.
Results
IL-10 is essential for the regulation of experimental
arthritis
It is well documented that mice lacking IL-10 have a
predisposition to immune-driven colitis and inflamma-
tion of the gut [16,30,31]. Furthermore, it has been
shown that CIA develops with increased incidence and
severity in IL-10 deficient animals [12,13]. Unlike the
wild type animals, the IL-10-/- animals do not enter
remission (when inflammation has subsided) and, as
such, joint swelling and redness does not permanently
recede. In order to unravel the relative contribution of
endogenous B cell derived IL-10 in a polyarthritis
model, we generated mixed bone marrow chimera mice
with IL-10 knocked-out specifically on B cells. As a con-
trol we generated bone marrow chimera mice with a
normal WT B cell compartment. We have previously
published that both WT B cell and IL-10-/- B cell ani-
mals show no major differences in either T or B cell
phenotypes either in naïve or immunized animals (Addi-
tional file 1[19]). Furthermore, the WT B cell chimeric
mice developed CIA with the same incidence and sever-
ity as WT mice that have not undergone any irradiation
procedures.
The CIA clinical scores and number of affected paws
for IL-10-/- B cell mice as compared to the WT B cell
mice were significantly increased (Figure 1A). In addi-
tion to this, IL-10-/- B cell mice produce increased anti-
collagen antibodies, especially of the pathogenic IgG2a
class (Figure 1B). The histological analysis revealed an
exacerbated disease in IL-10-/- B cell mice as shown by
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increased cellular infiltration and the loss of joint archi-
tecture in affected paws of IL-10-/- B cell chimeric mice
compared to WT B cell mice (Figure 1C). The majority
of the joints from the IL-10-/- B cell chimeric mice
group were severely damaged, exhibiting proliferation of
the pannus and accumulation of inflammatory cells, in
contrast the WT B cell group the displayed minimal
thickening of the cartilage and cellular infiltration (Fig-
ure 1C).
Pro-inflammatory cytokines IFNg and IL-17 are increased
in arthritic IL-10-/- B cell animals
Pathogenesis of arthritis is very dependent upon the
secretion of pro-inflammatory cytokines and the subse-
quent recruitment of inflammatory cells [32]. IL-17 and
IFNg are both potent pro-inflammatory cytokines that
recruit T cells and macrophages to the site of inflamma-
tion resulting in both inflammation and joint destruc-
tion, key indicators of arthritic disease. Using
intracellular cytokine staining it was demonstrated that
the IL-10-/- B cell mice with arthritis had an increased
CD4+ IFNg producing population (Figure 2A, B). We
found increased levels of Th1 cells in the LN of arthritic
IL-10-/- B cell mice compared to WT B cell mice at
days 12, 35 and 45 post-immunization with collagen
(Additional file 2). Moreover, there was a major increase
in secreted IFNg from IL-10-/- B cell mice as compared
to WT B cell mice, as observed in LN culture superna-
tant (Figure 2C). To confirm that IL-10-/-B cell mice
present with dysregulated IFNg production in vivo, we
administered biotin-anti-IFNg-labelled antibodies. Mice
were bled 12 hours later and serum levels of cytokine-
biotin-anti-cytokine mAb complexes were determined
by ELISA [33]. The results in Figure 2D demonstrate
that during the acute phase of inflammation a significant
increase of circulating IFNg in IL-10-/-B cell compared
to WT B cell mice was reported, revealing a mechanism
employed by Bregs to control disease.
Figure 1 Lack of endogenous B cell-derived IL-10 results in exacerbated CIA. A. Chimeric mice were generated that lacked IL-10 specifically
on B cells. Mean clinical score for CIA and numbers of diseased paws are shown. Data are expressed as mean ± SEM (n = 20, cumulative data
from four separate experiments with n = 5 per experimental group). Data were compared by statistical analysis using the Fisher test. * P < 0.05.
B. On Day 45 following immunization, mice were bled and the serum levels of total IgG1 and IgG2a CII-specific IgG antibodies were measured
by ELISA. Data are expressed as mean ± SEM (n = 20, cumulative data from four separate experiments with n = 5 per experimental group). Data
were compared by statistical analysis using the unpaired t test. * P < 0.05. C. The gradation of arthritis was scored from 0 to 4 according to the
intensity of lining layer hyperplasia, mononuclear cell infiltration and pannus formation. Data are expressed as mean ± SEM (n = 20, cumulative
data from four separate experiments with n = 5 per experimental group). Representative histological sections are also shown.
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Additionally, investigation of IL-17 levels clearly
demonstrated an increase in IL-17 production, as seen
by both multiplex bead array and IL-17 intracellular
staining, in the IL-10-/- B cell mice (Figure 2A-C). Th17
cells were only significantly increased in the LN, but not
the spleen, of arthritic IL-10-/- B cell mice compared to
WT B cell mice at days 12, 35 and 45 post-immuniza-
tion with collagen (Additional file 2 and data not
shown). Therefore, in addition to IFNg, IL-17 could also
play an important role in both the increased
inflammation and tissue destruction seen in the IL-10-/-
B cell mice. However, the percentage and number of
CD4+ IFNg+ IL-17+ double producing cells was not sig-
nificantly different in the WT B cell and IL-10-/- B cell
mice (data not shown).
Regulatory T cells are reduced in IL-10-/- B cell animals
Analysis of CD4+ derived IL-10 by flow cytometry
showed that the IL-10-/- B cell mice have a decreased


















































































































































Figure 2 Lack of B cell-derived IL-10 results in increased Th17 and Th1 responses. A. A total of 35 days after CIA induction, draining
lymph node cells were excised and cultured with PMA plus ionomycin in the presence of Brefeldin A for five hours. The intracellular levels of
IFNg and IL-17 were measured. Dot plots are gated on the CD4+ population. B. Numbers indicate percentages or absolute numbers of cells in
the quadrants. Data show mean ± SEM (n = 4), representative of four experiments. Data were compared by statistical analysis using the unpaired
t test. *** P < 0.001. C. Supernatant was collected from lymph node cells stimulated in vitro for 48 hours with anti-CD3, and then secreted IFNg
and IL-17 was measured by cytokine FlowCytomix kit. Data show mean ± SEM (n = 4), representative of four experiments. Data were compared
by statistical analysis using the unpaired t test. ** P < 0.01. D. Additionally, a BD in vivo cytokine capture assay was used to assess in vivo levels
of IFNg over a 12-hour period. The mean levels of IFNg-conjugated to antibody in serum are shown ± SEM (n = 5), representative of two
separate experiments. Data were compared by statistical analysis using the unpaired t test. * P < 0.05.
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(Figure 3A, B). This was demonstrated at an early time
point (Day 12 post- immunization) and during CIA dis-
ease (Day 35) and 45 days post-immunization (Addi-
tional file 2). This reduction in IL-10 secretion was also
confirmed using multiplex bead array on LN culture
supernatants (Figure 3B). Interestingly, this reduction in
CD4+ T cell derived IL-10 is only observed in the LN
cells and not in splenocytes. The reduction in CD4+ T
cell derived IL-10 is of particular interest as it suggests
that B-cell-derived IL-10 is essential for the develop-
ment of these anti-inflammatory CD4+ IL-10+ cells. This
clearly corroborates previous data showing that IL-10
secreting T2-MZP Bregs have the ability to promote
Tr1 cell development in vitro [19,34].
It is interesting to note that FoxP3+Treg numbers are
not reduced in the LN of IL-10-/- B cell mice with CIA
(Figure 3C). We did not see any significant differences
in FoxP3+Treg numbers in the LN of IL-10-/- B cell
mice compared to WT B cell mice on days 12, 35 or 45
post-immunization with collagen (Additional file 2). We
also compared FoxP3+Treg numbers in the spleen and
were unable to see any differences in IL-10-/- B cell
mice compared to WT B cell mice with CIA (data not
shown). Moreover, neither the suppressive function of
these Tregs (Figure 3D) nor in vivo levels of IL-2 (Figure
3E) were modulated in these animals. We have pre-
viously published that during the development of anti-
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Figure 3 Lack of B cell-derived IL-10 results in decreased Tr1 responses, however FoxP3+ Tregs are unaffected. A. A total of 35 days
after CIA induction, draining lymph node cells were excised and cultured with PMA plus ionomycin in the presence of Brefeldin A for five hours.
The CD4+ T cell population was identified using anti-CD4 FITC mAb and intracellular levels of IL-10 were measured. B. Numbers indicate
percentages of cells in the quadrants. Data shown mean ± SEM (n = 4), are representative of four experiments. Data were compared by
statistical analysis using the unpaired t test. *** P < 0.001. In addition, supernatant was collected from lymph node cells stimulated in vitro for 48
hours with anti-CD3, and then secreted IL-10 was measured by cytokine FlowCytomix kit. Data show mean ± SEM (n = 4), and are representative
of four experiments. Data were compared by statistical analysis using the unpaired t test. *** P < 0.001. C. Tregs were assessed using anti-CD25,
anti-CD4 and anti-FoxP3 mAb. Numbers indicate percentages of CD4 gated FoxP3+ cells or the absolute number of cells in a draining lymph
node. Data show mean ± SEM (n = 4), and are representative of four experiments. D. Spleens were taken from IL-10-/- B cell and WT B cell
animals and used to isolate CD25+ Treg cells using Milteyi Biotech magnetic beads. T-effector cells were isolated from immunized WT B6 mice
using the same process. The cells were cultured for 72 hours with anti-CD3 antibody (1 μg/ml). For 12 hours before harvesting cells were pulsed
with (3H) thymidine. Data shown are mean ± SEM of triplicate wells and are representative of two independent experiments. E. Additionally, a
BD in vivo cytokine capture assay was used to assess in vivo levels of IL-2 over a 12-hour period. The mean levels of IL-2-conjugated to antibody
in serum are shown ± SEM (n = 4), are representative of two separate experiments. Data were compared by statistical analysis using the
unpaired t test.
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a decrease in FoxP3+ Treg numbers and expression of
FoxP3 specifically at the site of inflammation (both the
synovial membrane of the affected knee and the inguinal
LN draining that knee) [19].
We did not see differences in number or function of
FoxP3+ Tregs during CIA development in IL-10-/- B cell
mice. It is important to note that splenocytes and lymph
node cells from these IL-10-/- B cell animals do have
normal proliferative responses to anti-CD3 (Additional
file 1B). Taken together these data suggest that FoxP3-
CD4+ IL-10 secreting Tr1 population is preferentially
affected by B cell- derived IL-10 during CIA.
Discussion
The importance of IL-10 in disease control has been
clearly demonstrated by the use of IL-10-/- animals. We
and others have shown that immune mediated colitis
[16,30], EAE [15] and experimental arthritis [12] are
exacerbated in these animals. However, this does not
resolve the question of which IL-10 producing cell types
are able to control inflammation.
Our results take advantage of chimeric animals that
lack IL-10 specifically in their B cells. These animals
had increased pro-inflammatory cytokines and antibo-
dies in circulation, firmly establishing the importance of
B cell derived IL-10 in regulating disease (Figures 1B
and 2).
In a colitis model, TCR-/- μMT mice develop a more
severe disease than an only-TCR-/- mouse, indicating
that B cells are as important as T cells in this inflamma-
tory disease [35]. Interestingly, the IL-10-/- B cell mice
developed a “colitis-like” disease with symptoms includ-
ing rectal pro-lapse with some bleeding, sticky stool
consistency, increased intestinal-gas (seen by dissection)
and loss of body weight (data not shown). This supports
the idea that B cell derived IL-10 is an important com-
ponent of the hierarchy that regulates and suppresses
the immune system, a concept that has been proved
numerous times in transfer experiments [9,17] and dis-
ease induction in μMT mice [35,36]. It even suggests
that in certain inflammatory models IL-10 secreting
Bregs can be apical to regulatory T cells in prevention
of autoimmunity and the maintenance of tolerance [37].
It is well established that IL-10 producing Tr1 cells
control the expansion of Teff cells and reduce the pro-
duction of proinflammatory cytokines in vitro [38-42].
However, to date there is a scarcity of information
about the stimuli promoting in vivo differentiation of
Tr1 and whether they are promoted by other cells.
Here, our data confirm and expand upon the impor-
tance of Bregs in the differentiation and maintenance of
Tr1 cells in vivo in the context of chronic disorders
[19,34,43]. Therefore, taking into account our data and
those already available in the literature, it is feasible to
speculate that IL-10 producing B cells may control the
regulatory hierarchy, including the proper development
of anti-inflammatory T cells, leading to the maintenance
of tolerance. This combined information reveals a con-
flicting hypothesis to research that attributes Tregs as
the most important component of immune regulation
[44], and that B cells only have a pathogenic role in
autoimmune disease [45].
Of interest, unlike in AIA where animals display a
reduction in both the number of FoxP3+ Tregs and
their expression of FoxP3+ in IL-10-/- B cell mice com-
pared to WT B cell mice, the number of FoxP3+ Tregs
and FoxP3+ expression were similar in both groups dur-
ing CIA. The discrepancy between the results in these
two models could be due to several reasons. The course
of arthritis is very different in the two diseases. Mice
immunized with collagen in CFA develop disease three-
to-four weeks post-immunization, whereas mice with
AIA are assessed five days post immunization. In addi-
tion, it is possible to obtain a sufficient number of cells
for flow cytometry analysis from the synovia (obtained
from the knee) in mice developing AIA, we were unable
to assess the frequencies of Tregs in the synovia of mice
with CIA. Thus, timing and location could account for
the differential data on Tregs in the IL-10-/-B cell mice
in the two models. Nevertheless, in both an acute
inflammatory model and a systemic experimental arthri-
tis, IL-10-/- B cell mice have an exacerbated arthritis
phenotype.
Conclusions
These data shed some light on the mechanism of action
of IL-10- secreting regulatory B cells. We have shown
that in IL-10-/- B cell mice T cell differentiation is
skewed to pro-inflammatory Th1 and Th17 subtypes,
whereas regulatory Tr1 cells are reduced as compared
to WT B cell animals (Figures 2 and 3A, B). These
increased inflammatory conditions result in exacerbated
arthritis in IL-10-/- B cell mice as compared to WT B
cell mice (Figure 1). These data confirm previous find-
ings from this laboratory, and others, establishing the
power of B cell produced IL-10 in maintenance of toler-
ance and prevention of multiple experimental autoim-
mune diseases [9,10,19,20,34,43,46,47].
Additional material
Additional file 1: Supplemental Data 1. Data to demonstrate that B
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Additional file 2: Supplemental Data 2. Data showing the percentage
of FoxP3+ Tregs and CD4- derived IL-10, IFNg and IL-17 on days 12, 35
and 45 post-immunization for CIA.
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